HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.
Speaker at Pharma Conferences - Shayan Fakhraei Lahiji
Yonsei University, Korea, Republic of
Title : Valproic acid encapsulated biodegradable microneedles for treatment of androgenetic alopecia


There are numerous genetic and environmental factors responsible for occurrence of male pattern hair loss known as androgenetic alopecia. Despite considerable medical advancements, the current treating agents, are limited by unsatisfactory cure rate and potential side effects. Valproic Acid, a well-kwon FDA approved anticonvulsant drug, was recently shown to induce hair follicle regrowth with a higher efficiency compared with current therapeutics including Minoxidil. Valproic acid activates several pathways including Wnt/β-catenin which is essential for hair growth. Although the exact action mechanism of valproic acid is not fully understood, previous studies suggested that application of valproic acid inhibits expression of glycogen synthase kinase 3β (GSK-3β), which upregulates β-catenin levels, leading to enhanced hair follicle transition from telogen (rest) to anagen (active) phase. Currently, topical application is the only available administration route of valproic acid to induce hair regrowth. Skin, as a protective barrier of body, however, limits the permeation efficiency of topically applied valproic acid. Thus, to improve its delivery efficiency, we encapsulated valproic acid within dissolving microneedles and applied them onto the skin by utilizing a micro-pillar based applicator. Dissolving microneedles are polymeric biodegradable micro dimensioned needles that encapsulate drugs and release them beneath the skin upon application in a minimally invasive manner. Carboxymethyl cellulose was used as backbone material of dissolving microneedles encapsulated with 50 μl of valproic acid. We found that by encapsulation of valproic acid within dissolving microneedles, the expression level of β-catenin, alkaline phosphatase, proliferating cell nuclear antigen, loricrin and hair follicle stem cell markers, including keratin 15, and CD34 that are responsible for hair growth were remarkably increased compared with the topical application.
Audience take away:
• An introduction to a novel drug delivery system, known as microneedle.
• Potential of dissolving microneedles in improving delivery efficiency of various sort of drugs, proteins, and vaccines.
• A new insight into androgenetic alopecia treatment technologies.


Dr. Shayan F. Lahiji is a postdoctoral associate at Yonsei University in the Department of Biotechnology. Dr. Lahiji’s research is focused on the design and development of novel patient-friendly drug delivery systems, known as microneedles. He has developed various technologies to pave the road for replacing hypodermic needles with painless and environmentally-friendly dissolving microneedles. So far, Dr. Lahiji has successfully encapsulated hair-loss treatment agents, insulin, and anti-wrinkle compounds within microneedles. Currently, he is involved in various projects to customize the previously-developed technologies and launch a product that is focused on the market needs. 
    Since 2014, Dr. Lahiji has published 5 papers as first author, 9 papers as co-author, and applied 4 patents in Korea, U.S., Japan, Europe and China. In addition, he has been the recipient of several awards, including “the best researcher award” at the 3rd World Biotechnology Conference, “the young researcher award” at the 8th Pharmaceutics & Novel Drug Delivery Systems conference, “the best research award” from Yonsei University, and “the best academic poster” from BK21 PLUS.